Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition.

Buck SB, Hardouin C, Ichikawa S, Soenen DR, Gauss CM, Hwang I, Swingle MR, Bonness KM, Honkanen RE, Boger DL.

J Am Chem Soc. 2003 Dec 24;125(51):15694-5.

PMID:
14677930
2.

Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and( beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors.

Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, Fischer KL, Boger DL, Honkanen RE.

J Pharmacol Exp Ther. 2009 Oct;331(1):45-53. doi: 10.1124/jpet.109.155630. Epub 2009 Jul 10.

3.

Total synthesis and evaluation of cytostatin, its C10-C11 diastereomers, and additional key analogues: impact on PP2A inhibition.

Lawhorn BG, Boga SB, Wolkenberg SE, Colby DA, Gauss CM, Swingle MR, Amable L, Honkanen RE, Boger DL.

J Am Chem Soc. 2006 Dec 27;128(51):16720-32.

4.

Importance of the beta12-beta13 loop in protein phosphatase-1 catalytic subunit for inhibition by toxins and mammalian protein inhibitors.

Connor JH, Kleeman T, Barik S, Honkanen RE, Shenolikar S.

J Biol Chem. 1999 Aug 6;274(32):22366-72.

5.
6.

Fostriecin: chemistry and biology.

Lewy DS, Gauss CM, Soenen DR, Boger DL.

Curr Med Chem. 2002 Nov;9(22):2005-32. Review.

PMID:
12369868
7.

Asymmetric total synthesis of (+)-fostriecin.

Reddy YK, Falck JR.

Org Lett. 2002 Mar 21;4(6):969-71.

PMID:
11893198
9.

Catalyst-controlled asymmetric synthesis of fostriecin and 8-epi-fostriecin.

Maki K, Motoki R, Fujii K, Kanai M, Kobayashi T, Tamura S, Shibasaki M.

J Am Chem Soc. 2005 Dec 7;127(48):17111-7.

PMID:
16316259
10.

Fostriecin, an inhibitor of protein phosphatase 2A, limits myocardial infarct size even when administered after onset of ischemia.

Weinbrenner C, Baines CP, Liu GS, Armstrong SC, Ganote CE, Walsh AH, Honkanen RE, Cohen MV, Downey JM.

Circulation. 1998 Sep 1;98(9):899-905.

12.

Protein phosphatase inhibitors calyculin A and fostriecin protect rabbit cardiomyocytes in late ischemia.

Armstrong SC, Gao W, Lane JR, Ganote CE.

J Mol Cell Cardiol. 1998 Jan;30(1):61-73.

PMID:
9500865
13.

Positive regulation of IkappaB kinase signaling by protein serine/threonine phosphatase 2A.

Kray AE, Carter RS, Pennington KN, Gomez RJ, Sanders LE, Llanes JM, Khan WN, Ballard DW, Wadzinski BE.

J Biol Chem. 2005 Oct 28;280(43):35974-82. Epub 2005 Aug 26.

15.

Antitumor antibiotic fostriecin covalently binds to cysteine-269 residue of protein phosphatase 2A catalytic subunit in mammalian cells.

Takeuchi T, Takahashi N, Ishi K, Kusayanagi T, Kuramochi K, Sugawara F.

Bioorg Med Chem. 2009 Dec 1;17(23):8113-22. doi: 10.1016/j.bmc.2009.09.050. Epub 2009 Oct 3.

PMID:
19857968
16.
17.

Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells.

Messner DJ, Romeo C, Boynton A, Rossie S.

J Cell Biochem. 2006 Sep 1;99(1):241-55.

PMID:
16598789
19.

Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Theobald B, Bonness K, Musiyenko A, Andrews JF, Urban G, Huang X, Dean NM, Honkanen RE.

Mol Cancer Res. 2013 Aug;11(8):845-55. doi: 10.1158/1541-7786.MCR-13-0032. Epub 2013 May 13.

20.

Phoslactomycin targets cysteine-269 of the protein phosphatase 2A catalytic subunit in cells.

Teruya T, Simizu S, Kanoh N, Osada H.

FEBS Lett. 2005 Apr 25;579(11):2463-8.

Supplemental Content

Support Center